A recent study indicates that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop conventional diet and exercise programs.
Published data in a major medical journal shows that while obese people often shed a large proportion of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing such medications need to be aware of the potential of fast weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to original weight within about 18 months.
Comparing Therapies
The study, which reviewed dozens of trials involving thousands of patients, compared the results of GLP-1 agonists with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone typically have a slower weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Nutrition scientists believe the mechanism of the jabs explains the amplified rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means appetite is uncontrolled, making excessive eating far more likely."
An Ongoing Condition?
The NHS recommend the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts contend that, due to the significant potential of relapse, the therapy is often life-long.
This perspective is reinforced by pharmaceutical companies, who note that the results "underscore the persistent character of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
People who have stopped the medication explain a intense resurgence of cravings.
"I experienced something that goes on and I was suddenly extremely hungry," said a patient.
This challenge is exacerbated if individuals have not established permanent dietary or behavioural modifications during treatment.
Significant Interest
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts stress that while the jabs are potent tools for weight loss, they are not a standalone cure and long-term success relies on ongoing lifestyle management.
